Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW3011 in Patients With Non-transfusion-dependent β-Thalassemia
NCT06772766Phase 1Recruiting
- Sponsor
- Mabwell
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 9MW3011 in beta thalassemia intermedia (NTDT) (4 cohorts), sponsored by Mabwell. Primary endpoints: Adverse Event (including serious adverse event) at Day 169, Number of subjects with abnormal vital signs at Day 169 and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
9MW3011
03
Conditions
beta thalassemia intermedia (NTDT)
Beyond the preview
Go deeper on NCT06772766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772766.